Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Hematology

View By:YearCompanyConditionsTherapeutic AreasDrug Names

Refludan

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Hoechst Marion Roussel
Approval Status: Approved March 1998
Treatment Area: heparin-induced thrombocytopenia type II

General Information

Refludan has been approved for the treatment of heparin-induced thrombocytopenia type II (HIT type II). HIT type II is a rare, allergy-like adverse reaction to heparin, a standard anticoagulant therapy. HIT type II is characterized by a rapid and serious decline in the blood's platelet count, leading to an increased risk of severe thromboembolic complications.